<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04474938</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-AL2020</org_study_id>
    <nct_id>NCT04474938</nct_id>
  </id_info>
  <brief_title>Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis</brief_title>
  <official_title>Efficacy of Daratumumab Combined With Bortezomib and Dexamethasone in Patients With Mayo 04 Stage III Light Chain Amyloidosis: a Prospective Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xian-Janssen Pharmaceutical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with light chain (AL) amyloidosis who have advanced cardiac damage are at risk of&#xD;
      premature mortality. There is ongoing unmet need for effective therapies to rapidly induce&#xD;
      deep hematologic response and decrease the early death rate. Lately, trials of daratumumab in&#xD;
      newly-diagnosed and relapsed/refractory AL amyloidosis have shown dramatic response rates.&#xD;
      However, the benefits of upfront daratumumab in stage III AL patients, especially stage IIIb&#xD;
      patients, have not yet been demonstrated definitely in prospective studies. Therefore, we&#xD;
      designed a phase II, single arm clinical trial to investigate the efficacy and safety of&#xD;
      co-administration of daratumumab with bortezomib and dexamethasone (BD) regimen in&#xD;
      treatment-naïve patients with Mayo 04 stage III AL amyloidosis. We planned to enroll 40&#xD;
      patients, who would receive daratumumab and BD treatment for a total duration of 12 months.&#xD;
      The primary endpoint is complete response and very good partial response at 3 months after&#xD;
      treatment initiation. Secondary endpoints include overall survival, organ response and&#xD;
      adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematologic very good partial response or better at 3 months after treatment initiation</measure>
    <time_frame>3 months</time_frame>
    <description>Very good partial response or better is defined as complete response or very good partial response. Complete response: normalization of free light chain levels and ratio with negative serum and urine immunofixation electrophoresis. Very good partial response: difference between involved and uninvolved free light chains (dFLC) less than 40 mg/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major organ deterioration progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality within 1 month from treatment initiation</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality within 3 months from treatment initiation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality within 6 months from treatment initiation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic very good partial response or better at 1 month after treatment initiation</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic very good partial response or better at 6 months after treatment initiation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic very good partial response or better at 12 months after treatment initiation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stringent dFLC response</measure>
    <time_frame>1 year</time_frame>
    <description>dFLC declined to less than 10 mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hematologic response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ response at 3 months after treatment initiation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ response at 6 months after treatment initiation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ response at 12 months after treatment initiation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cardiac response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to liver response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to renal response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>treatment initiation to 30 days after last dose of treatment</time_frame>
    <description>Adverse events are collected until 30 days after last dose of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Amyloidosis; Systemic</condition>
  <arm_group>
    <arm_group_label>Dara-BD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab combined with bortezomib and dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>16mg/kg, QW Cycles 1-2 (28 days/cycle), Q2W Cycles 3-6, and Q4W thereafter for up to 1 year</description>
    <arm_group_label>Dara-BD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>1.3mg/m2 of subcutaneous bortezomib on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles</description>
    <arm_group_label>Dara-BD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20mg of dexamethasone on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles</description>
    <arm_group_label>Dara-BD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old adults.&#xD;
&#xD;
               -  Biopsy proved treatment-naïve AL amyloidosis.&#xD;
&#xD;
               -  Mayo 2004 stage III.&#xD;
&#xD;
               -  dFLC &gt; 50mg/L.&#xD;
&#xD;
               -  Patient must provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-morbidity of uncontrolled infection.&#xD;
&#xD;
          -  Co-morbidity of other active malignancy.&#xD;
&#xD;
          -  Co-diagnosis of multiple myeloma or waldenstrom macroglobulinemia.&#xD;
&#xD;
          -  Co-morbidity of grade 2 or 3 atrioventricular block.&#xD;
&#xD;
          -  Co-morbidity of sustained or recurrent nonsustained ventricular tachycardia.&#xD;
&#xD;
          -  Seropositive for human immunodeficiency virus.&#xD;
&#xD;
          -  Seropositive for hepatitis B (positive test for HBsAg). Participants with resolved&#xD;
             infection (ie, HBsAg negative but positive for anti-HBc and/or anti-HBs) must be&#xD;
             screened of HBV-DNA. Those who are PCR positive will be excluded.&#xD;
&#xD;
          -  Seropositive for hepatitis C (except in the setting of a sustained virologic&#xD;
             response).&#xD;
&#xD;
          -  Grade 2 or higher neuropathy according to National Cancer Institute Common Terminology&#xD;
             Criteria for Adverse Events.&#xD;
&#xD;
          -  Neutrophil &lt;1×10E9/L，hemoglobin &lt; 7g/dL，or platelet &lt; 75×10E9/L.&#xD;
&#xD;
          -  Severely compromised hepatic or renal function: ALT or AST &gt; 2.5 × ULN, total&#xD;
             bilirubin &gt; 1.5mg/dL，or eGFR &lt; 40mL/min (those with renal dysfunction due to renal&#xD;
             involvement or renal hypoperfusion from cardiac amyloidosis could be included)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Li, MD</last_name>
    <phone>+86-18610852525</phone>
    <email>lijian@pumch.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaini Shen, MD</last_name>
    <phone>+86-13693339884</phone>
    <email>shenkaini3@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaini Shen, MD</last_name>
      <phone>86-13693339884</phone>
      <email>shenkaini3@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>light chain amyloidosis</keyword>
  <keyword>daratumumab</keyword>
  <keyword>bortezomib</keyword>
  <keyword>hematologic response</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

